OPEN LABEL, TWO COHORT (WITH AND WITHOUT IMIGLUCERASE), MULTICENTER STUDY TO EVALUATE PHARMACOKINETICS (PK), SAFETY, AND EFFICACY OF ELIGLUSTAT IN PEDIATRIC PATIENTS WITH GAUCHER DISEASE (GD) TYPE 1 (GD1) AND TYPE 3 (GD3)

Registry ID

EFC13738 (ELIKIDS)

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

GENZYME, A SANOFI COMPANY

Start date

2019-04-30

Completion date

2026-04-13

Last update

2017-10-02

Conditions

• GAUCHER DISEASE TYPE 1

Related clinical trials

• A PHASE 3 SAFETY AND EFFICACY TRIAL OF FLT201 GENE THERAPY IN PATIENTS WITH GAUCHER DISEASE TYPE 1
• AN ADAPTIVE, OPEN-LABEL, MULTINATIONAL PHASE 1/2 STUDY OF THE SAFETY AND EFFICACY OF EX VIVO, LENTIVIRAL VECTOR-MEDIATED GENE THERAPY AVR-RD-02 FOR SUBJECTS WITH TYPE 1 GAUCHER DISEASE

View on source registry